Overview

A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this Study is to help answer the following research question(s). - How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes? - How does LY2189265 affect how the body handles metformin (a drug used to treat Type 2 diabetes)? - Is LY2189265 safe and are any side effects associated with it? The study will be participant-blind in Week 1, and participant- and investigator-blind from Week 2 through Week 5. Each participant will receive placebo on Week 1 and once-weekly doses of LY2189265 or Placebo on Weeks 2 to 5. Participants taking metformin for the treatment of Type 2 Diabetes Mellitus (T2DM) will continue taking metformin as part of the study.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Dulaglutide